CN100523214C - 冠状动脉疾病的预测 - Google Patents

冠状动脉疾病的预测 Download PDF

Info

Publication number
CN100523214C
CN100523214C CNB988049155A CN98804915A CN100523214C CN 100523214 C CN100523214 C CN 100523214C CN B988049155 A CNB988049155 A CN B988049155A CN 98804915 A CN98804915 A CN 98804915A CN 100523214 C CN100523214 C CN 100523214C
Authority
CN
China
Prior art keywords
coronary artery
allelotrope
artery disease
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988049155A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255948A (zh
Inventor
希拉·E·弗朗西斯
戴维·C·克罗斯曼
戈登·W·杜夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Medical Science Systems Inc
Original Assignee
Interleukin Genetics Inc
Medical Science Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc, Medical Science Systems Inc filed Critical Interleukin Genetics Inc
Publication of CN1255948A publication Critical patent/CN1255948A/zh
Application granted granted Critical
Publication of CN100523214C publication Critical patent/CN100523214C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB988049155A 1997-03-10 1998-03-09 冠状动脉疾病的预测 Expired - Fee Related CN100523214C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/813,456 1997-03-10
US08/813,456 US6210877B1 (en) 1997-03-10 1997-03-10 Prediction of coronary artery disease

Publications (2)

Publication Number Publication Date
CN1255948A CN1255948A (zh) 2000-06-07
CN100523214C true CN100523214C (zh) 2009-08-05

Family

ID=25212420

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988049155A Expired - Fee Related CN100523214C (zh) 1997-03-10 1998-03-09 冠状动脉疾病的预测

Country Status (22)

Country Link
US (1) US6210877B1 (enExample)
EP (1) EP0983381B1 (enExample)
JP (2) JP4250765B2 (enExample)
CN (1) CN100523214C (enExample)
AR (1) AR011943A1 (enExample)
AT (1) ATE370246T1 (enExample)
AU (1) AU738875B2 (enExample)
BR (1) BR9808313A (enExample)
CA (1) CA2282746C (enExample)
DE (2) DE983381T1 (enExample)
DK (1) DK0983381T3 (enExample)
EA (1) EA199900813A1 (enExample)
ES (1) ES2156843T3 (enExample)
GR (1) GR20010300016T1 (enExample)
IL (1) IL131745A0 (enExample)
MX (1) MXPA99008223A (enExample)
NO (1) NO994365L (enExample)
NZ (1) NZ337642A (enExample)
PL (1) PL335603A1 (enExample)
PT (1) PT983381E (enExample)
WO (1) WO1998040517A1 (enExample)
ZA (1) ZA981937B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
GB9723835D0 (en) * 1997-11-13 1998-01-07 Nicklin Martin Interleukin knockout
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
CA2328955C (en) * 1998-04-21 2008-03-18 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
AU778975B2 (en) * 1999-02-10 2004-12-23 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an IL-1B mutation
WO2000071753A2 (en) * 1999-05-24 2000-11-30 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
IL147182A0 (en) * 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
KR101019131B1 (ko) * 2001-11-19 2011-03-07 인터레우킨 제네틱스, 인코포레이티드 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
EP1327639A1 (en) * 2002-01-15 2003-07-16 Bayer Ag Prediction of cardiovascular disease by genetic polymorphisms in cardiovascular associated genes
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
JP2005529585A (ja) * 2002-01-25 2005-10-06 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１遺伝子群ならびに関連する炎症性多型およびハプロタイプ
WO2004029618A2 (en) * 2002-09-30 2004-04-08 Novartis Ag Methods to predict cholesterol elevations during immunosuppressant therapy
US20050053956A1 (en) * 2002-11-13 2005-03-10 Dietz Harry C. Detection of a predisposition for the development of coronary artery disease
EP1592706A2 (en) * 2003-02-03 2005-11-09 Bayer HealthCare AG Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
WO2004081186A2 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
CA2566257A1 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2007050794A2 (en) * 2005-10-25 2007-05-03 Interleuken Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
RU2310862C1 (ru) * 2006-05-02 2007-11-20 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ выявления риска развития ишемической болезни сердца
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
ES2431671T3 (es) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
WO2009061506A2 (en) * 2007-11-08 2009-05-14 Interleukin Genetics, Inc. Diagnostics for aging-related dermatologic disorders
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
CN102747075B (zh) * 2012-06-07 2014-07-23 中国医学科学院阜外心血管病医院 与冠心病相关的6号染色体易感区域标签单核苷酸多态性位点及其组成的单体型与应用
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
CN106202936A (zh) * 2016-07-13 2016-12-07 为朔医学数据科技（北京）有限公司 一种疾病风险预测方法及系统
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
EP3980561A1 (en) 2019-06-06 2022-04-13 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
CN110277137B (zh) * 2019-06-13 2022-03-18 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种用于检测冠心病的基因芯片信息处理系统及方法
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4623619A (en) 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
GB9301453D0 (en) * 1993-01-26 1993-03-17 Clonit Spa Nucleotide proves
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
AU738875B2 (en) 2001-09-27
PT983381E (pt) 2007-11-26
EA199900813A1 (ru) 2000-06-26
DK0983381T3 (da) 2007-12-17
CA2282746C (en) 2009-02-24
NO994365D0 (no) 1999-09-09
DE983381T1 (de) 2000-11-09
CN1255948A (zh) 2000-06-07
ATE370246T1 (de) 2007-09-15
IL131745A0 (en) 2001-03-19
US6210877B1 (en) 2001-04-03
JP2009077727A (ja) 2009-04-16
NO994365L (no) 1999-11-09
AU6457498A (en) 1998-09-29
WO1998040517A1 (en) 1998-09-17
ES2156843T1 (es) 2001-08-01
JP4250765B2 (ja) 2009-04-08
CA2282746A1 (en) 1998-09-17
GR20010300016T1 (en) 2001-04-30
EP0983381A1 (en) 2000-03-08
AR011943A1 (es) 2000-09-13
DE69838250D1 (de) 2007-09-27
JP2001514522A (ja) 2001-09-11
EP0983381B1 (en) 2007-08-15
DE69838250T2 (de) 2008-05-08
ES2156843T3 (es) 2008-04-16
MXPA99008223A (es) 2003-07-21
PL335603A1 (en) 2000-05-08
BR9808313A (pt) 2000-05-16
ZA981937B (en) 1999-09-06
EP0983381A4 (en) 2004-05-12
NZ337642A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
CN1255948A (zh) 冠状动脉疾病的预测
Maron et al. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives
Menon et al. Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology
Pontremoli et al. Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension
JP2002500513A (ja) ＩＬ−１遺伝子座（ｇｅｎｅｌｏｃｉ）多型性に関連する炎症性疾患の予測
CN101679971A (zh) 青光眼恶化风险的判定方法
EP1578918A2 (en) Atherosclerotic phenotype determinative genes and methods for using the same
CA2416545A1 (en) Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
Ma et al. Molecular convergence of risk variants for congenital heart defects leveraging a regulatory map of the human fetal heart
Guicciardi et al. Genetic background of mitral valve prolapse
US5712098A (en) Hereditary hemochromatosis diagnostic markers and diagnostic methods
JP6141275B2 (ja) 線維症感受性ｉｌ２２ｒａ２遺伝子およびその使用
Roberts Molecular genetics. Therapy or terror?
US5955266A (en) Use of platelet polymorphism P1A2 to diagnose risk of thrombotic disease
CN113355332B (zh) Heg1基因突变体及其应用
ES2340459B1 (es) Metodo para diagnosticar o determinar la predisposicion genetica a desarrollar miocardiopatia hipertrofica.
Mestroni et al. Molecular genetics of dilated cardiomyopathies
JP4657757B2 (ja) 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
CN101871003A (zh) 预测中国人2型糖尿病易感性的试剂盒及引物
US6866999B2 (en) Method for identifying increased risk of death from community acquired pneumonia
Liu et al. The rs1800470 Polymorphism of TGF‐β1 Influences the Incidence of Peri‐Implantitis
Hu et al. Detection of ST-2 and TGF-β2 levels in patients with atrial fibrillation and their correlation with atrial fibrillation remodeling.
Wax et al. The molecular genetics of sepsis: Clinical epidemiology considerations
CZ9903182A3 (cs) Předpověď onemocnění věnčitých tepen
Blanckenberg Molecular genetics of arrhythmogenic right ventricular cardiomyopathy in South Africa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Inteleukin Genetics

Applicant before: Medical Science Systems, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MEDICAL SCIENCE SYSTEMS, INC. TO: INTERLEUKIN GENETICS LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20150309

EXPY Termination of patent right or utility model